It’s well reported that PAX5 promoter is hypermethylated in various cancer types, including hepatocellular carcinoma, gastric cancer and esophageal cancer, resulted in the down-regulated expression of PAX5 [42–44]. This evidence concerns the gene PAX5 and gastric cancer.